MDACC Study No:2011-0253 ( NCT No: NCT01398462)
Title:A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia-2 (CMML-2), Myelodysplastic Syndrome Having Failed Hypomethylating Treatment (MDS), and High-Risk Myelofibrosis (MF)
Principal Investigator:Jorge Cortes
Treatment Agent:CWP232291
Study Status:Closed
Study Description:The goal of this clinical research study is to learn the highest tolerable dose
of the drug CWP232291 that can be given to patients with relapsed or refractory
AML CMML-2, MDS, or MF disease. The safety of CWP232291 will also be studied to
understand the best way to give the drug and also see what the best dose will
be for patients with hematologic disease.

CWP232291 is designed to target and block the function of messenger molecules
in cancer cells. This may slow the growth of tumors or kill the cancer cells.
This is the first study using CWP232291 in humans.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:CWP232291
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:JW Pharmaceutical Corporation
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults